120 related articles for article (PubMed ID: 25302034)
1. Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review.
Hoch JS; Brown MB; McMahon C; Nanson J; Rozmovits L
Curr Oncol; 2014 Oct; 21(5):263-6. PubMed ID: 25302034
[TBL] [Abstract][Full Text] [Related]
2. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.
Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW
Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796
[TBL] [Abstract][Full Text] [Related]
3. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
Lexchin J
BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
[TBL] [Abstract][Full Text] [Related]
4. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example.
McDonald H; Charles C; Elit L; Gafni A
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27489586
[TBL] [Abstract][Full Text] [Related]
5. Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review.
Hoch JS; Sabharwal M
Curr Oncol; 2013 Apr; 20(2):121-4. PubMed ID: 23559876
[No Abstract] [Full Text] [Related]
6. The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison.
Skedgel C
Curr Oncol; 2016 Oct; 23(5):322-328. PubMed ID: 27803596
[TBL] [Abstract][Full Text] [Related]
7. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
Niraula S
Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
[TBL] [Abstract][Full Text] [Related]
8. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
Niraula S; Nugent Z
J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
[No Abstract] [Full Text] [Related]
9. Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review.
Rocchi A; Chabot I; Glennie J
Clinicoecon Outcomes Res; 2015; 7():287-98. PubMed ID: 26082654
[TBL] [Abstract][Full Text] [Related]
10. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).
Masucci L; Beca J; Sabharwal M; Hoch JS
Pharmacoecon Open; 2017 Dec; 1(4):255-263. PubMed ID: 29441502
[TBL] [Abstract][Full Text] [Related]
11. Determinants of the Cancer Drug Funding Process in Canada.
Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
Jenei K; Meyers DE
BMJ Open; 2023 Oct; 13(10):e066378. PubMed ID: 37844982
[TBL] [Abstract][Full Text] [Related]
13. Impact of rarity on Canadian oncology health technology assessment and funding.
Keech J; Dai WF; Trudeau M; Mercer RE; Naipaul R; Wright FC; Ferguson SE; Darling G; Gavura S; Eisen A; Kouroukis CT; Beca J; Chan KKW
Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32779560
[TBL] [Abstract][Full Text] [Related]
14. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
[TBL] [Abstract][Full Text] [Related]
15. Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs.
Saluja R; Jiao T; Koshy L; Cheung M; Chan KKW
Curr Oncol; 2021 Jan; 28(1):606-618. PubMed ID: 33498460
[TBL] [Abstract][Full Text] [Related]
16. Oncology drug health technology assessment recommendations: Canadian versus UK experiences.
Chabot I; Rocchi A
Clinicoecon Outcomes Res; 2014; 6():357-67. PubMed ID: 25075196
[TBL] [Abstract][Full Text] [Related]
17. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
Raymakers AJN; Regier DA; Peacock SJ
Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
[TBL] [Abstract][Full Text] [Related]
18. [Reluctant partner: Canada's relationship with the Pan American Health Organization (PAHO)].
Dmitrienko K
Hist Cienc Saude Manguinhos; 2006; 13(3):717-32. PubMed ID: 17117515
[TBL] [Abstract][Full Text] [Related]
19. Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study.
Lexchin J
PLoS One; 2019; 14(2):e0212399. PubMed ID: 30768629
[TBL] [Abstract][Full Text] [Related]
20. Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups.
Mercer RE; Chambers A; Mai H; McDonald V; McMahon C; Chan KKW
Value Health; 2020 Sep; 23(9):1157-1162. PubMed ID: 32940233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
